Key Considerations Compounded semaglutide is not equivalent to FDA-approved semaglutide products Safety, efficacy, and quality may vary among compounded formulations Use requires medical supervision and ongoing monitoring Cost, availability, and formulation differ depending on the pharmacy and prescription Patients should discuss FDA-approved options, compounded alternatives, potential risks, and expected outcomes with their healthcare provider before starting treatment
In reviewing the content of the claims in this batch of warning letters, most of the concerning language on online websites advertising these products that was flagged by the FDA is unsurprising, including: Named the brand product as a comparative reference or therapeutic equivalent Stated the compounded product was a generic of the brand product Included efficacy claims for the compounded product Used the words FDA-approved in the advertising copy But some of the language that was flagged by the FDA was less direct, with the FDAs expressed concern being that the advertising may have given the impression of FDA approval
Therefore, Erysipelatoclostridium and other Erysipelotrichaceae may be favored in young children, potentially contributing to increased lipid absorption and food efficiency
Interact with other medications an individual might be taking
FSC, forward scatter
The impact on various IBS subtypes, methods of action, and long-term effects require more investigation
